Jonathan Schwartz

Jonathan Schwartz is the current Chief Medical Officer and SVP of Clinical Development at Rocket Pharmaceuticals. Jonathan has over 15 years of experience in the pharmaceutical industry, specifically in clinical development.

Schwartz began their career in 1999 as an Associate Professor at Mount Sinai Medical Center. In 2006, they joined ImClone Systems as Vice President. During their time there, they oversaw the development of Ramucirumab from end-of-phase 1 through multiple phase 3 global trials. Ramucirumab was approved by the FDA in April 2014. Schwartz also oversaw the development of several other anticancer monoclonal antibodies during their time at ImClone Systems.

In 2014, Schwartz left ImClone Systems to join Stemline Therapeutics as Vice President of Clinical Development. During their time at Stemline, they designed and oversaw first-in-human dose-finding, safety and preliminary efficacy studies for SL-401 (immunoconjugate for hematologic malignancies) and SL-701 (peptide vaccine for high-grade brain cancer [GBM]). Jonathan also successfully submitted an IND for a first-in-human study for SL-801 (reversible nuclear export inhibitor). Schwartz left Stemline in 2016 to join Rocket Pharmaceuticals.

Jonathan Schwartz's educational career includes earning a Doctor of Medicine (MD) from Washington University in St. Louis and a Bachelor of Arts (B.A.) in American Civilization from Brown University.

Their manager is Gaurav Shah, CEO & President. They work with Ramji Krishnan - VP, Manufacturing and Manufacturing Sciences, John Militello - VP, Finance & Senior Controller, and Deirdre W. O’donnell - Director of Operations.